These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 20960887)

  • 21. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women.
    Ridker PM; Hennekens CH; Buring JE; Rifai N
    N Engl J Med; 2000 Mar; 342(12):836-43. PubMed ID: 10733371
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PTX3 predicts severe disease in febrile patients at the emergency department.
    de Kruif MD; Limper M; Sierhuis K; Wagenaar JF; Spek CA; Garlanda C; Cotena A; Mantovani A; ten Cate H; Reitsma PH; van Gorp EC
    J Infect; 2010 Feb; 60(2):122-7. PubMed ID: 19961874
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Should we measure CRP levels to assess cardiovascular risk?
    Hadley RD; Graber MA
    JAAPA; 2003 Jan; 16(1):17-9. PubMed ID: 12635434
    [No Abstract]   [Full Text] [Related]  

  • 24. Multiple biomarkers and cardiovascular risk.
    Austin MJ; Heneghan MA
    N Engl J Med; 2008 Aug; 359(7):760-1; author reply 761. PubMed ID: 18711791
    [No Abstract]   [Full Text] [Related]  

  • 25. The long pentraxin PTX3 as a link among innate immunity, inflammation, and female fertility.
    Bottazzi B; Bastone A; Doni A; Garlanda C; Valentino S; Deban L; Maina V; Cotena A; Moalli F; Vago L; Salustri A; Romani L; Mantovani A
    J Leukoc Biol; 2006 May; 79(5):909-12. PubMed ID: 16478917
    [TBL] [Abstract][Full Text] [Related]  

  • 26. C-reactive protein and coronary heart disease.
    Foody JM; Gotto AM; Wenger N
    N Engl J Med; 2004 Jul; 351(3):295-8; author reply 295-8. PubMed ID: 15257565
    [No Abstract]   [Full Text] [Related]  

  • 27. Is pentraxin 3 a cardiovascular marker in patients with chronic Chagas disease?
    Lidani KC; Beltrame MH; Luz PR; Sandri TL; Nisihara RM; de Messias-Reaso IJ
    Int J Cardiol; 2015; 190():233-5. PubMed ID: 25920034
    [No Abstract]   [Full Text] [Related]  

  • 28. Prognostic value of pentraxin 3 in patients with chronic heart failure.
    Kotooka N; Inoue T; Aoki S; Anan M; Komoda H; Node K
    Int J Cardiol; 2008 Oct; 130(1):19-22. PubMed ID: 18045709
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The long pentraxin PTX-3 in prevalent hemodialysis patients: associations with comorbidities and mortality.
    Suliman ME; Qureshi AR; Carrero JJ; Bárány P; Yilmaz MI; Snaedal-Jonsdottir S; Alvestrand A; Heimbürger O; Lindholm B; Stenvinkel P
    QJM; 2008 May; 101(5):397-405. PubMed ID: 18292098
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Change in cardiovascular risk status after dental clearance.
    Ellis JS; Averley PA; Preshaw PM; Steele JG; Seymour RA; Thomason JM
    Br Dent J; 2007 May; 202(9):543-4. PubMed ID: 17496863
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The long pentraxin PTX3: a modulator of the immunoinflammatory response in atherosclerosis and cardiovascular diseases.
    Norata GD; Garlanda C; Catapano AL
    Trends Cardiovasc Med; 2010 Feb; 20(2):35-40. PubMed ID: 20656213
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure.
    Suzuki S; Takeishi Y; Niizeki T; Koyama Y; Kitahara T; Sasaki T; Sagara M; Kubota I
    Am Heart J; 2008 Jan; 155(1):75-81. PubMed ID: 18082493
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recurrent cellulitis and the role of pentraxin 3 and C-reactive protein.
    Agilli M; Aydin FN
    J Infect; 2015 May; 70(5):546-7. PubMed ID: 25583210
    [No Abstract]   [Full Text] [Related]  

  • 34. [CRP and cardiovascular prevention in the elderly].
    Benoit MO
    Ann Biol Clin (Paris); 2001; 59(4):469-73. PubMed ID: 11470644
    [No Abstract]   [Full Text] [Related]  

  • 35. Multiple biomarker panels for cardiovascular risk assessment.
    de Lemos JA; Lloyd-Jones DM
    N Engl J Med; 2008 May; 358(20):2172-4. PubMed ID: 18480211
    [No Abstract]   [Full Text] [Related]  

  • 36. The long pentraxin PTX3 in vascular pathology.
    Mantovani A; Garlanda C; Bottazzi B; Peri G; Doni A; Martinez de la Torre Y; Latini R
    Vascul Pharmacol; 2006 Nov; 45(5):326-30. PubMed ID: 17023219
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events.
    Ridker PM; Rifai N; Rose L; Buring JE; Cook NR
    N Engl J Med; 2002 Nov; 347(20):1557-65. PubMed ID: 12432042
    [TBL] [Abstract][Full Text] [Related]  

  • 38. C-reactive protein: a new golden marker of cardiovascular risk.
    Gomes MC
    Rev Port Cardiol; 2002 Nov; 21(11):1329-46. PubMed ID: 12564084
    [TBL] [Abstract][Full Text] [Related]  

  • 39. C-reactive protein: a nontraditional serum marker of cardiovascular risk.
    de Ferranti SD; Rifai N
    Cardiovasc Pathol; 2007; 16(1):14-21. PubMed ID: 17218210
    [TBL] [Abstract][Full Text] [Related]  

  • 40. C-reactive protein in cardiovascular risk prediction. Zooming in and zooming out.
    Maseri A
    Ital Heart J; 2001 Mar; 2(3):155-6. PubMed ID: 11305525
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.